Patents Assigned to Wake Forest University
  • Modified siRNA molecules incorporating 5-fluoro-2?-deoxyuridine residues to enhance cytotoxicity
    Patent number: 9096853
    Abstract: A synthesized siRNA molecule having the sense strand with one or more uridine bases replaced by one or more respective nucleoside analogs, such as 5-fluoro-2?-deoxyuridine (FdU).
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: August 4, 2015
    Assignees: U.S. Department of Veterans Affairs, University of Pittsburgh-Of the Commonwealth System of Higher Education, Wake Forest University Health Sciences
    Inventors: John C. Schmitz, Sr., Edward Chu, William H. Gmeiner
  • Natural orifice transluminal endoscopic devices for closure of luminal perforations and associated methods
    Patent number: 9072517
    Abstract: Devices include at least two spaced apart flexible legs formed of a shape memory material, each leg having a respective free end configured to engage local tissue. The devices can also include at least one resilient member having opposing end portions, a respective end portion being attached to each leg at a location away from the free end. The resilient member is configured to take on a stretched configuration inside an endoscope during delivery. Alternatively or additionally, the devices include a cinch that is configured to snugly hold portions of both legs to force the legs closer together.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: July 7, 2015
    Assignee: Wake Forest University Health Sciences
    Inventor: Mohammed Abdul Qadeer
  • Keratin biomaterials for cell culture and methods of use
    Patent number: 9068162
    Abstract: Provided are keratin compositions useful in cell culture. In some embodiments the keratins are biocompatible, promote cell growth, promote cell adhesion and provide an excellent substrate for cell culture. Keratin compositions described herein may be used as coatings, gels, three-dimensional scaffolds, additives to cell culture media, microcarriers, etc. The keratin substrates may also be used to deliver cells, e.g., for cell therapy applications.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: June 30, 2015
    Assignee: Wake Forest University Health Sciences
    Inventor: Mark E. Van Dyke
  • Transcriptional profiling of stem cells and their multilineage differentiation
    Patent number: 9062346
    Abstract: The present invention concerns methods of screening cells for differentiation or de-differentiation, and/or for status as a pluripotent or multipotent (e.g., “stem”) cell, by detecting the differential expression (e.g., upregulation, downregulation) of genes.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: June 23, 2015
    Assignee: Wake Forest University Health Sciences
    Inventors: Jason Hipp, Shay Soker
  • Regeneration of pancreatic islets by amniotic fluid stem cell therapy
    Patent number: 9056093
    Abstract: A method of treating diabetes in a mammalian subject is carried out by: (a) providing mammalian amniotic fluid stem cells, and then (b) administering the cells to the subject in an amount effective to treat diabetes. Optionally, the cells may be differentiated into pancreatic-like cells or at least treated to initiate subsequent differentiation into-pancreatic-like cells, prior to administration.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: June 16, 2015
    Assignee: Wake Forest University Health Sciences
    Inventors: Anthony Atala, Anna Milanesi, Shay Soker
  • Non-viral delivery of compounds to mitochondria
    Patent number: 9045552
    Abstract: A conjugate comprises: (a) a mitochondrial membrane-permeant peptide; (b) an active agent or compound of interest such as a detectable group or mitochondrial protein or peptide; and (c) a mitochondrial targeting sequence linking said mitochondrial membrane-permeant peptide and said active mitochondrial protein or peptide. The targeting sequence is one which is cleaved within the mitochondrial matrix, and not cleaved within the cellular cytoplasm, of a target cell into which said compound is delivered. Methods of use of such compounds are also described.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: June 2, 2015
    Assignee: Wake Forest University
    Inventor: R. Mark Payne
  • Inkjet gene printing
    Patent number: 9045757
    Abstract: Provided herein are methods and apparatuses for transfecting a cell with a compound of interest by stressing the cell, e.g. with shear stress. The compound of interest may be nucleic acids, proteins, molecules, nanoparticles, drugs, etc., or any combination thereof. Methods of printing cells with an inkjet printing device are also provided, wherein at least a portion of viable cells (preferably at least 1%) are transfected with a compound of interest. Preferably, at least 25% of the cells are viable after printing. In addition, methods of forming an array of viable cells are provided wherein at least a portion of the viable printed cells (preferably at least 1%) are transfected with at least one compound of interest.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: June 2, 2015
    Assignee: Wake Forest University Health Sciences
    Inventors: Tao Xu, James J. Yoo, Anthony Atala
  • Production of tissue engineered digits and limbs
    Patent number: 9039782
    Abstract: The invention pertains to methods of producing artificial composite tissue constructs that permit coordinated motion. Biocompatable structural matrices having sufficient rigidity to provide structural support for cartilage-forming cells and bone-forming cells are used. Biocompatable flexible matrices seeded with muscle cells are joined to the structural matrices to produce artificial composite tissue constructs that are capable of coordinated motion.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: May 26, 2015
    Assignee: Wake Forest University Health Sciences
    Inventors: Anthony Atala, James J. Yoo, Grace Lim, Sang Jin Lee
  • USE OF NITRITE SALTS FOR THE TREATMENT OF CARDIOVASCULAR CONDITIONS
    Publication number: 20150125553
    Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.
    Type: Application
    Filed: January 5, 2015
    Publication date: May 7, 2015
    Applicants: The Government of the United States of America as represented by the Secretary of the Department of, The Board of Supervisors of Louisiana State Univer and Agricultural and Mechanical College, Acting t, The UAB Research Foundation, Loma Linda University, Wake Forest University
    Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
  • Method of labeling sulfenic acid-containing proteins and peptides
    Patent number: 9023653
    Abstract: A method of labeling a sulfenic acid (—SOH) group of a cysteine residue in a protein; or peptide, comprises contacting said protein or peptide with a beta-ketoester to covalently couple said beta-ketoester to said cysteine residue and form a beta-ketoester-labeled cysteine residue in said protein or peptide.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: May 5, 2015
    Assignee: Wake Forest University Health Sciences
    Inventors: Cristina M. Furdui, Allen W. Tsang, Jiang Qian
  • Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders
    Patent number: 9012647
    Abstract: Disclosed are nitroxide modified NSAID compounds of the formula (I) or a pharmaceutically acceptable salt or enantiomer thereof: in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and n are defined herein and pharmaceutical compositions thereof. Further disclosed is a method of treating or preventing various disorders, such as inflammation, cancer, diabetes, a cardiovascular disorder, weight gain, polyps, and/or chronic pain, in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt or enantiomer of formula (I). A method of imaging the compound or pharmaceutically acceptable salt or enantiomer of formula (I) in the body of the animal is also provided.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: April 21, 2015
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Wake Forest University
    Inventors: David A. Wink, Wilmarie Flores-Santana, S. Bruce King, Murali Krishna Cherukuri, James B. Mitchell
  • Method of treating acute myelogenous leukemia
    Patent number: 9012422
    Abstract: The present invention relates to active compounds for treating acute myelogenous leukemia (AML) in a subject in need thereof and methods of treating AML carried out by administering the subject an active compound in an amount effective to treat the leukemia. The active compound comprises a 10-mer oligonucleotide covalently linked via 3? to 5? phosphodiester linkages of 5-fluorodeoxyuridine, FdUMP[10], or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: April 21, 2015
    Assignee: Wake Forest University Health Sciences
    Inventors: William H. Gmeiner, Timothy S. Pardee
  • Compounds useful for multi-level specific targeting of cancer cells
    Patent number: 9005600
    Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: April 14, 2015
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
  • Inkjet printing of tissues and cells
    Patent number: 9005972
    Abstract: Provided herein is an apparatus for printing cells which includes an electrospinning device and an inkjet printing device operatively associated therewith. Methods of making a biodegradable scaffold having cells seeded therein are also provided. Methods of forming microparticles containing one or more cells encapsulated by a substrate are also provided, as are methods of forming an array of said microparticles.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: April 14, 2015
    Assignee: Wake Forest University Health Sciences
    Inventors: Tao Xu, James J. Yoo, Anthony Atala, Dennis Dice
  • Optoelectronic devices and applications thereof
    Patent number: 8993363
    Abstract: In one aspect, optoelectronic devices are described herein. In some embodiments, an optoelectronic device comprises a fiber core, a radiation transmissive first electrode surrounding the fiber core, at least one photosensitive inorganic layer surrounding the first electrode and electrically connected to the first electrode, and a second electrode surrounding the inorganic layer and electrically connected to the inorganic layer. In some embodiments, the device comprises a photovoltaic cell.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: March 31, 2015
    Assignee: Wake Forest University
    Inventor: David L Carroll
  • Silicone-peroxide compositions for long-term, controlled oxygen release
    Patent number: 8986725
    Abstract: A composite for delivering extended-release of oxygen is disclosed. The composite can include a biocompatible polymeric support having a plurality of solid peroxide particles suspended therein. The polymer support can exhibit an oxygen tension value of at least 40 mmHg for a period of 14 days. The weight ratio of biocompatible polymeric support to solid peroxide particles can range from 1:1 to 99:1. Also disclosed is a method of using the composite to deliver oxygen to cells in both in vivo and in vitro environments.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: March 24, 2015
    Assignees: University of Miami, Wake Forest University Health Sciences
    Inventors: Cherie L. Stabler, Benjamin S. Harrison, Christopher A. Fraker, Eileen Pedraza, Camillo Ricordi
  • Compositions and methods for treating obesity and diabetes
    Patent number: 8987198
    Abstract: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: March 24, 2015
    Assignees: The Administrators of the Tulane Educational Fund, The United States Department of Agriculture, Wake Forest University Health Sciences, Nume Health, LLC
    Inventors: Matthew E. Burow, Stephen M. Boue, Thomas T. Y. Wang, Deepak Bhatnagar, Charles E. Wood, Mark L. Helman
  • Methods of treatment for hemolysis
    Patent number: 8980871
    Abstract: Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds preferentially react with cell-free OxyHb, as compared to OxyHb encapsulated in a red blood cell, and reacts with MetHb to form iron-nitrosyl Hb or nitrite bound MetHb. It has also been found that such compounds reduce cell-free Hb and hemolysis. Active compounds are also contemplated for use in combination therapies, for example, in combination with the administration of red blood cells and/or an agent that promotes hematopoiesis, or in combination with the administration of a nitric oxide donor.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: March 17, 2015
    Assignees: Wake Forest University Health Sciences, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Daniel B. Kim-Shapiro, S. Bruce King, Daniel A. Sweeney, Mark T. Gladwin
  • Nerve regeneration employing keratin biomaterials
    Patent number: 8968764
    Abstract: A keratin hydrogel matrix serves as an effective acellular scaffold for axonal regeneration and facilitates functional nerve recovery.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: March 3, 2015
    Assignee: Wake Forest University Health Sciences
    Inventor: Mark E. Van Dyke
  • Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
    Patent number: 8957044
    Abstract: The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: February 17, 2015
    Assignees: Wake Forest University Health Sciences, Genethon, Children's Medical Center Corporation
    Inventors: Martin K. Childers, Alan H. Beggs, Ana Maria Buj Bello